TCR immunotherapy is emerging as a promising, targeted approach for treating solid tumours and other indications.

Comprehensive Synovial Sarcoma Pipeline Landscape Report For 2024: In-Depth Analysis Of 20+ Pipeline Drugs And 15+ Companies ...

Previous studies reported that cellular communication network factor 1 (CCN1) is overexpressed in the endothelial cells and synovial tissue of patients with rheumatoid arthritis (RA). French ...

To determine which product to use when, it is important to have a current understanding of osteoarthritis (OA). It has been ...

Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

Adaptimmune Therapeutics’ lete-cel data achieves primary endpoint in pivotal phase 2 IGNYTE-ESO trial: Philadelphia Friday, November 15, 2024, 13:00 Hrs [IST] Adaptimmune Therap ...

Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA ...

Adaptimmune’s Phase II trial of lete-cel showed a 42% response rate in synovial sarcoma and MRCLS, with strong median ...

Adaptimmune Therapeutics is prepping for another FDA submission after 42% of patients with sarcoma responded to the company's ...

Tecelra®, a single infusion, is the first new treatment option for synovial sarcoma in more than a decade and the first engineered cell therapy for solid tumors. 9 Sarcoma centers of excellence across ...

MRCLS had clinical responses with lete-celResults include six complete responses (6/64); twenty-one partial responses ...

We're having problems with persistence of cells, and we think it's that suppressive microenvironment that we have to deal ...